BRCA1 and cancer: We frequently observed allelic deletions that are positioned in CFSs, which was more frequently observed in HR-deficient cancers when compared to HR-proficient cancers (19% vs 15%, p = 7.55E−11; Fig. 6B), and more frequently observed in BRCA1/2 mutant cancers (Supplementary Fig. 6B).